曲妥珠单抗联合DS化疗方案对HER-2阳性晚期胃癌患者的影响
|
摘要
目的分析曲妥珠单抗联合DS化疗方案对人表皮生长因子受体2(HER-2)阳性晚期胃癌患者血清肿瘤标志物及功能状态(KPS评分)影响。方法选取2016年9月～2018年4月本院HER-2阳性晚期胃癌患者62例,按治疗方法不同分为联合组(n=31)与DS组(n=31)。DS组给予DS化疗方案治疗,联合组在DS组基础上接受曲妥珠单抗治疗,观察对比两组治疗前后糖类抗原199(CA199)、癌胚抗原(CEA)、胃癌抗原(CA724)及KPS评分。结果治疗后联合组KPS评分高于DS组;治疗后联合组血清CA199、CEA、CA724水平较DS组低,组间比较差异均有统计学意义(P <0.05)。结论曲妥珠单抗联合DS化疗方案应用于HER-2阳性晚期胃癌患者,可降低血清CA724、CA199、CEA水平,提高生存质量。
Objective To analyze the effect of Trastuzumab combined with DS chemotherapy on serum tumor markers and functional status(KPS rating) of advanced gastric cancer patients with positive human epidermal growth factor receptor2(HER-2). Methods 62 patients with HER-2 positive advanced gastric cancer from September 2016 to April 2018 were selected and divided into combined group(n=31) and DS group(n=31) according to different treatment Methods. DS group was treated with DS chemotherapy, while combined group was treated with Trastuzumab on the basis of DS group. The carbohydrate antigen199(CA199), carcinoembryonic antigen(CEA), gastric cancer antigen(CA724) and KPS scores before and after treatment were observed and compared between the two groups. Results KPS score of combined group was higher than DS group after treatment. After treatment, the levels of serum CA199, CEA and CA724 in the combined group were lower than those in the DS group, and the differences between the groups were statistically significant(P < 0.05). Conclusion The application of Trastuzumab combined with DS chemotherapy in HER-2 positive advanced gastric cancer patients can reduce serum CA724,CA199 and CEA levels and improve the quality of life.
Objective To analyze the effect of Trastuzumab combined with DS chemotherapy on serum tumor markers and functional status(KPS rating) of advanced gastric cancer patients with positive human epidermal growth factor receptor2(HER-2). Methods 62 patients with HER-2 positive advanced gastric cancer from September 2016 to April 2018 were selected and divided into combined group(n=31) and DS group(n=31) according to different treatment Methods. DS group was treated with DS chemotherapy, while combined group was treated with Trastuzumab on the basis of DS group. The carbohydrate antigen199(CA199), carcinoembryonic antigen(CEA), gastric cancer antigen(CA724) and KPS scores before and after treatment were observed and compared between the two groups. Results KPS score of combined group was higher than DS group after treatment. After treatment, the levels of serum CA199, CEA and CA724 in the combined group were lower than those in the DS group, and the differences between the groups were statistically significant(P < 0.05). Conclusion The application of Trastuzumab combined with DS chemotherapy in HER-2 positive advanced gastric cancer patients can reduce serum CA724,CA199 and CEA levels and improve the quality of life.
引文
[1]魏微,闫泽强.曲妥珠单抗联合IP化疗方案治疗HER-2阳性晚期胃癌的疗效观察[J].现代药物与临床,2017,32(3):505-508.
[2]李龙,展昊,龙勃,等.曲妥珠单抗联合化疗治疗HER-2阳性晚期胃癌的Meta分析[J].中国循证医学杂志,2017,17(1):40-46.
[3]中国抗癌协会临床肿瘤学协作专业委员会.HER2阳性晚期胃癌分子靶向治疗的中国专家共识[C]//全国临床肿瘤学大会暨2012年csco学术年会.2012.
[4]李国立,相小松.晚期胃癌综合治疗国内外指南解析[J].中国实用外科杂志,2017,37(10):1128-1131.
[5]张苗苗,王兴元,邢镨元,等.多西他赛联合奥沙利铂和5-氟尿嘧啶方案治疗晚期胃癌41例[J].中国新药杂志,2012,21(7):767-771.
[6]邱佳宁,韩涛,刘璐,等.曲妥珠单抗联合多西他赛加顺铂治疗HER-2阳性晚期胃癌相关射血分数降低与疗效关系[J].临床军医杂志,2017,45(1):34-37.
[7]顾胜龙,赵蕊,应苗法,等.曲妥珠单抗对肿瘤靶向治疗的研究进展[J].基础医学与临床,2018,38(05):140-144.
[8]Urabe M,Ushiku T,Seto Y,et al.HER-2阳性胃癌对曲妥珠单抗为基础化疗的病理反应[J].临床与实验病理学杂志,2017(5):510-510.
[9]曾晓华,李康宪.曲妥珠单抗联合化疗治疗HER2阳性晚期胃癌临床有效率的Meta分析[J].临床和实验医学杂志,2017,16(17):1722-1725.
[10]罗玉凤.血清癌胚抗原、糖类抗原724和糖类抗原199对胃癌的早期诊断价值[J].检验医学与临床,2017,14(23):3557-3558.
[11]周红林,岳文彬,金静.癌胚抗原细胞黏附分子1和CD105对胃癌进展的作用[J].中国现代普通外科进展,2018,21(5).
[12]李争,李强,肖强.甲胎蛋白、癌胚抗原和糖链抗原19-9联合检测诊断消化系统恶性肿瘤的价值分析[J].癌症进展,2017,15(4):432-434.
[2]李龙,展昊,龙勃,等.曲妥珠单抗联合化疗治疗HER-2阳性晚期胃癌的Meta分析[J].中国循证医学杂志,2017,17(1):40-46.
[3]中国抗癌协会临床肿瘤学协作专业委员会.HER2阳性晚期胃癌分子靶向治疗的中国专家共识[C]//全国临床肿瘤学大会暨2012年csco学术年会.2012.
[4]李国立,相小松.晚期胃癌综合治疗国内外指南解析[J].中国实用外科杂志,2017,37(10):1128-1131.
[5]张苗苗,王兴元,邢镨元,等.多西他赛联合奥沙利铂和5-氟尿嘧啶方案治疗晚期胃癌41例[J].中国新药杂志,2012,21(7):767-771.
[6]邱佳宁,韩涛,刘璐,等.曲妥珠单抗联合多西他赛加顺铂治疗HER-2阳性晚期胃癌相关射血分数降低与疗效关系[J].临床军医杂志,2017,45(1):34-37.
[7]顾胜龙,赵蕊,应苗法,等.曲妥珠单抗对肿瘤靶向治疗的研究进展[J].基础医学与临床,2018,38(05):140-144.
[8]Urabe M,Ushiku T,Seto Y,et al.HER-2阳性胃癌对曲妥珠单抗为基础化疗的病理反应[J].临床与实验病理学杂志,2017(5):510-510.
[9]曾晓华,李康宪.曲妥珠单抗联合化疗治疗HER2阳性晚期胃癌临床有效率的Meta分析[J].临床和实验医学杂志,2017,16(17):1722-1725.
[10]罗玉凤.血清癌胚抗原、糖类抗原724和糖类抗原199对胃癌的早期诊断价值[J].检验医学与临床,2017,14(23):3557-3558.
[11]周红林,岳文彬,金静.癌胚抗原细胞黏附分子1和CD105对胃癌进展的作用[J].中国现代普通外科进展,2018,21(5).
[12]李争,李强,肖强.甲胎蛋白、癌胚抗原和糖链抗原19-9联合检测诊断消化系统恶性肿瘤的价值分析[J].癌症进展,2017,15(4):432-434.